Patents by Inventor Vimal Kaneria

Vimal Kaneria has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Linaclotide stable composition
    Patent number: 10272131
    Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 30, 2019
    Assignee: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Sanjay Poptani, Vimal Kaneria, T. Nathamani
  • Oral pharmaceutical dosage forms of budesonide
    Patent number: 10172802
    Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 8, 2019
    Assignee: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
  • PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATE
    Publication number: 20180369183
    Abstract: The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Rajamannar THENNATI, Shirish KULKARNI, Amol KULKARNI, Vimal KANERIA, Mukesh SHARMA
  • Pharmaceutical compositions of dimethyl fumarate
    Patent number: 10085961
    Abstract: The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 2, 2018
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
  • ORAL PHARMACEUTICAL DOSAGE FORMS OF BUDESONIDE
    Publication number: 20170281556
    Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 5, 2017
    Applicant: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
  • LINACLOTIDE STABLE COMPOSITION
    Publication number: 20170232058
    Abstract: A method of stabilizing linaclotide in a solid dosage form, said method comprising a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and b) converting the composition into a solid dosage form.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 17, 2017
    Applicant: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Sanjay Poptani, Vimal Kaneria, T. Nathamani
  • Oral pharmaceutical dosage forms of budesonide
    Patent number: 9707182
    Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: July 18, 2017
    Assignee: Sun Pharmaceutical Industries LTD.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
  • ORAL PHARMACEUTICAL DOSAGE FORMS OF BUDESONIDE
    Publication number: 20170071863
    Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 16, 2017
    Applicant: Sun Pharmaceutical Industries Ltd.
    Inventors: Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
  • PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATE
    Publication number: 20160346393
    Abstract: The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 1, 2016
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Rajamannar THENNATI, Shirish KULKARNI, Amol KULKARNI, Vimal KANERIA, Mukesh SHARMA
  • SUSTAINED RELEASE FORMULATIONS OF DIVALPROEX SODIUM
    Publication number: 20100172982
    Abstract: A sustained release tablet formulation comprising an inner phase comprising a mixture of divalproex or its pharmaceutically acceptable salt and a hydrophobic agent, and an outer phase comprising a hydrophilic polymer, wherein the hydrophobic agent is present in amount ranging from 6.3% to about 8.3% by weight of the formulation.
    Type: Application
    Filed: May 23, 2008
    Publication date: July 8, 2010
    Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Veera Babu Taduri, Deepak Gondaliya, Vimal Kaneria